President & Chief Executive Officer
Martin McGlynn joined StemCells, Inc. in January of 2001 as President and Chief Executive Officer and was elected to our Board of Directors on February 6, 2001. Mr. McGlynn has spent several decades in the life sciences industry in Europe, Canada and the United States. He began his career with Becton Dickinson, Ireland Ltd., and spent eight years in manufacturing operations. He joined Abbott Labs in 1977 where he held positions as General Manager, Abbott Ireland Ltd., President and General Manager of Abbott Canada Ltd. and Vice President of Abbott International Ltd. In 1990, he joined the BOC Group as President of Anaquest, Inc., a global leader in anesthesia and acute care pharmaceuticals headquartered in New Jersey. Mr. McGlynn joined the biotech industry in 1994 when he became President and Chief Executive Officer of Pharmadigm, Inc., a private, venture capital-backed company engaged in the research and development of a new class of anti-inflammatory agents. Mr. McGlynn is a native of Dublin, Ireland. He holds a Bachelor of Commerce degree from University College, Dublin. He is a former member of the Board of Directors of the Confederation of Irish Industries (CII) and the Pharmaceutical Manufacturers Association of Canada (PMAC), and currently serves as a member of the Board of the Alliance for Regenerative Medicine (ARM).
Ann Tsukamoto, PhD
Executive Vice President, Scientific and Strategic Alliances
Ann Tsukamoto joined StemCells, Inc. in 1998 as Senior Director, Scientific Operations, to help start the Company's California operations, and has since held several leadership roles at the Company. In June 2013, Dr. Tsukamoto was appointed Executive Vice President, Scientific and Strategic Alliances and is responsible for developing the Company's alliances with research institutions, corporations, government agencies, and disease foundations. From September 2008 to June 2013, she served as the Company's Executive Vice President of Research and Development. Under her direction, the Company identified and purified the human neural stem cell and populations of human liver and pancreatic cells with stem cell-like properties, successfully transitioned into clinical translation, and initiated and completed its first human clinical trials. Before joining the Company, Dr. Tsukamoto was a co-discoverer of the human hematopoietic stem cell while at SyStemix, Inc., a stem cell and gene therapy company. Dr. Tsukamoto received her PhD from the University of California, Los Angeles and did postdoctoral research with Dr. Harold Varmus at the University of California, San Francisco where she worked on the wnt-1 gene, which is a key player in the stem cell self-renewal pathway. Dr. Tsukamoto is an inventor on seven issued US patents related to the human hematopoietic stem cell and gene transfer methods.
Stewart Craig, PhD
Executive Vice President, Manufacturing Operations and Regulatory Affairs
Stewart Craig joined StemCells, Inc. in September 2008 in the role of Senior Vice President, Development and Operations. In June 2013, he was appointed Executive Vice President, Manufacturing Operations and Regulatory Affairs. In this role, he is responsible for process design and engineering, GMP manufacturing operations, regulatory affairs, quality systems, manufacturing facilities, and supply chain management. Dr. Craig has more than 28 years' of biotechnology industry experience in the research, development, manufacturing, delivery, and regulation of recombinant protein, antibody and cell-based therapeutic products. Before joining the Company, Dr. Craig served as Chief Technology Officer at Progenitor Cell Therapy, LLC (PCT), a contract service provider for the research, development, manufacture, and commercialization of cell-based therapies. Prior to joining PCT, Dr. Craig served for six years as Chief Operating Officer at Xcyte Therapies, Inc., a company developing cell-based therapeutic products for the treatment of cancer, immune dysfunction and other diseases. Prior to Xcyte Therapies, Dr. Craig served as Vice President, Development & Operations at Osiris Therapeutics, a mesenchymal stem cell therapy company. During this time, Dr. Craig was also a member of the US Pharmacopeia Expert Advisory Panel for Cell and Gene Therapy and was a co-author for the initial USP monograph on this subject. From 1994 to 1996, Dr. Craig served as Vice President, Product & Process Development at SyStemix, Inc., a stem cell and gene therapy company. From 1987 to 1993, Dr. Craig served in various research and development positions at British Biotech, PLC, working on the design, purification, characterization and clinical translation of recombinant therapeutic protein molecules. Dr. Craig received his B.Sc. in Biochemistry and PhD in Physical Biochemistry from the University of Newcastle upon Tyne, UK.
Executive Vice President and Chief Financial Officer
Greg Schiffman joined StemCells, Inc. January 2014. He has overall responsibility for corporate financial management, financial reporting and controls, investor relations, corporate communications and information technology. Greg Schiffman is a seasoned veteran in the healthcare industry, with over fifteen years of experience leading the financial operations and strategy of global, publicly-traded biotech and life science companies including Affymetrix and Applied Biosystems. In his most recent role as Executive Vice President and CFO of Dendreon Corporation, Dendreon secured marketing authorization from the FDA and the European Commission for the world’s first cell-based, autologous immunotherapy for prostate cancer. Prior to entering the healthcare field, Greg served in various roles at both Hewlett Packard and IBM including controller of Hewlett Packard’s European P.C. manufacturing and distribution operations in Grenoble, France and as manufacturing manager and controller of HP’s Netmetrix Division. Mr. Schiffman received a Bachelor of Science from De Paul University and a Master of Business Administration from the Kellogg School at Northwestern University.
Ken Stratton, Esq.
Ken Stratton joined StemCells, Inc. in February 2007. His primary responsibilities include overseeing the Company's legal operations and advising the Company and its management and directors on various compliance matters. He also serves as corporate secretary. In March 2008, he assumed responsibilities for the Human Resources function. Mr. Stratton was formerly Deputy General Counsel at Threshold Pharmaceuticals, Inc., and prior to that was Senior Legal Counsel for the vascular business unit of Medtronic, Inc., an international medical device manufacturer. Prior to joining industry, Mr. Stratton was a business attorney in private practice for ten years handling both transactional and litigation matters with corporate law firms in San Francisco and Palo Alto. He earned both his J.D. and M.B.A. in finance from New York University and his B.A. from the University of Pennsylvania.
Stephen Huhn, M.D., FACS, FAAP
Vice President, Head of CNS Clinical Research
Stephen Huhn joined StemCells, Inc. in January 2007 to direct the Company's preclinical and clinical development programs for CNS indications. Prior to joining the Company, he was Associate Professor of Neurosurgery at Stanford University and Chief of Pediatric Neurosurgery at the Lucile Salter Packard Children's Hospital. Dr. Huhn earned his M.D. at the University of Arizona in 1987 and completed a residency in Neurosurgery at the University of Maryland in 1993. He completed a fellowship in Neuro-Oncology at UCSF Medical Center in San Francisco and a fellowship in Pediatric Neurosurgery at Children's Memorial Hospital in Chicago, Northwestern University. Dr. Huhn is certified by the American Board of Neurological Surgery and the American Board of Pediatric Neurological Surgery. He is also a Fellow in the American College of Surgeons and the American Academy of Pediatrics. Dr. Huhn maintains a Consulting Associate Professor appointment with the Department of Neurosurgery at Stanford University.
Nobuko Uchida, Ph.D.
Vice President, Stem Cell Biology
Nobuko Uchida is responsible for the Company's discovery initiative focusing on identifying new stem or progenitor cells, as well as for characterizing the Company's human neural stem cell and candidate liver and pancreas stem cells. Dr. Uchida has been with the Company since 1998, and in 1999 she was the first to identify, by a combination of cell surface markers, the human neural stem cell. Dr. Uchida was previously employed at SyStemix, Inc. as a research scientist working on hematopoietic stem cell biology, and has worked in stem cell biology for the past 18 years. Dr. Uchida obtained her PhD in Cancer Biology from Stanford University and completed her post-doctoral training in the laboratory of Dr. Irving Weissman at the Stanford University School of Medicine.